WXIBF (WuXi Biologics (Cayman)) Long-Term Debt: $24 Mil (As of Dec. 2025)


WXIBF WuXi Biologics (Cayman) Inc WXIBF
97 GF Score
Price $4.60
GF Value $5.14
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Long-Term Debt?

WuXi Biologics (Cayman) WXIBF 97 Long-Term Debt is $24 Mil as of Dec. 2025. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $5.14 (Modestly Undervalued). The stock has 3 warning signs investors should review.

WuXi Biologics (Cayman)'s Long-Term Debt for the quarter that ended in Dec. 2025 was $24 Mil.

WuXi Biologics (Cayman)'s quarterly Long-Term Debt declined from Dec. 2024 ($28 Mil) to Jun. 2025 ($26 Mil) and declined from Jun. 2025 ($26 Mil) to Dec. 2025 ($24 Mil).

WuXi Biologics (Cayman)'s annual Long-Term Debt declined from Dec. 2023 ($220 Mil) to Dec. 2024 ($28 Mil) and declined from Dec. 2024 ($28 Mil) to Dec. 2025 ($24 Mil).

WuXi Biologics (Cayman)  (OTCPK:WXIBF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

WuXi Biologics (Cayman) Long-Term Debt Related Terms

WuXi Biologics (Cayman) Long-Term Debt Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Long-Term Debt Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.56 209.64 220.03 27.59 24.05

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 220.03 174.27 27.59 25.78 24.05
WXIBF
97GF Score
WuXi Biologics (Cayman) Inc WXIBF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $24 Mil mean?
WuXi Biologics (Cayman) (WXIBF) has a Long-Term Debt of $24 Mil as of Dec. 2025.
Is WuXi Biologics (Cayman)'s Long-Term Debt too high?
WuXi Biologics (Cayman)'s current Long-Term Debt is $24 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Long-Term Debt compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Long-Term Debt of $24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. WuXi Biologics (Cayman)'s current Long-Term Debt is $24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.14, compared to a current price of $4.60 — trading 10.5% below its estimated fair value. The current Long-Term Debt is $24 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Long-Term Debt is $24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $4.60 is trading 10.5% below its estimated GF Value™ of $5.14. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for WXIBF:

  • Long-Term Debt: $24 Mil
  • GF Value™: $5.14 vs. price of $4.60 (10.5% below fair value)
  • GF Score™: 97/100 with 3 warning signs

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score

Get the complete analysis for WXIBF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.60
Price
$5.14
GF Value